Xilio Therapeutics, Inc. XLO Q1 2026 earnings

FAQ

When did Xilio Therapeutics, Inc. report Q1 2026 earnings?

Xilio Therapeutics, Inc. (XLO) reported Q1 2026 earnings on May 12, 2026 before market open.

What were Xilio Therapeutics, Inc.'s Q1 2026 revenue and EPS?

Xilio Therapeutics, Inc. reported revenue of $12.7M and eps of $-0.58 for Q1 2026.

Did Xilio Therapeutics, Inc. beat estimates in Q1 2026?

Revenue beat the consensus estimate of $8.5M by $4.1M. EPS beat the consensus estimate of $-0.66 by $0.08.

How did Xilio Therapeutics, Inc.'s Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 331.7% from $2.9M a year earlier and eps declined 222.2% from $-0.18.

Where can I find Xilio Therapeutics, Inc.'s Q1 2026 SEC filings?

You can read the 8-K earnings release (0001193125-26-218194) and the 10-Q periodic report (0001193125-26-218200) directly on SEC EDGAR. The filing index links above go to sec.gov.